Author:
Caers Jo,Duray Elodie,Vrancken Louise,Marcion Guillaume,Bocuzzi Valentina,De Veirman Kim,Krasniqi Ahmet,Lejeune Margaux,Withofs Nadia,Devoogdt Nick,Dumoulin Mireille,Karlström Amelie Eriksson,D’Huyvetter Matthias
Abstract
Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a broad clinical application. In recent years, researchers have developed theranostic agents based on Ab fragments or small Ab mimetics such as peptides, affibodies or single-chain Abs with improved tumor-targeting capacities. Theranostics combine diagnostic and therapeutic capabilities into a single pharmaceutical agent; this dual application can be easily achieved after conjugation to radionuclides. The past decade has seen a trend to increased specificity, fastened pharmacokinetics, and personalized medicine. In this review, we discuss the different strategies introduced for the noninvasive detection and treatment of hematological malignancies by radiopharmaceuticals. We also discuss the future applications of these radiotheranostic agents.
Funder
Fonds De La Recherche Scientifique - FNRS
Fondation contre le Cancer
Fonds Léon Fredericq
Université de Liège
Fonds Wetenschappelijk Onderzoek
Subject
Immunology,Immunology and Allergy
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献